Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphoma

Results Establishing Lenalidomide Plus Rituximab as Superior Treatment in Non-Hodgkin LymphomaПодробнее

Obinutuzumab or Rituximab plus CHOP in 1st line DLBCL patients results of the Phase 3 GOYA trial AПодробнее

Obinutuzumab bests rituximab for PFS in follicular lymphomaПодробнее

RG6146 and venetoclax in DLBCLПодробнее

Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHLПодробнее

MURANO trial: Sustained disease survival in CLL following venetoclax plus rituximabПодробнее

Venetoclax plus rituximab or obinutuzumab in CLL after alloHCTПодробнее

Results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in CLLПодробнее

The Role of Venetoclax + Rituximab in CLLПодробнее

Findings From the RELEVANCE Trial in Follicular LymphomaПодробнее

Phase Ib trial of R-CHOP plus iberdomide or golcadomide in aggressive B-cell lymphomaПодробнее

Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphomaПодробнее

Debate: Is obinutuzumab superior to rituximab in lymphoma? - YesПодробнее

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZLПодробнее

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCLПодробнее

Venetoclax and obinutuzumab combination therapy for CLLПодробнее

Debate: Is obinutuzumab superior to rituximab in lymphoma? - NoПодробнее

Update on Venetoclax for CLLПодробнее

Venetoclax + rituximab for R/R CLL: 7-year results of the MURANO trialПодробнее